Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rbv Patients'

Rbv Patients published presentations and documents on DocSlides.

SOF + EBR + GZR + RBV
SOF + EBR + GZR + RBV
by test
N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...
PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
Daclatasvir + Sofosbuvir + RBV in GT3
Daclatasvir + Sofosbuvir + RBV in GT3
by sophia2
. with Advanced Liver Disease. ALLY-3+ Study. Phas...
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
by UnicornLove
C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...
Reddy KR. Lancet Infect Dis. 2015;15:27-35
Reddy KR. Lancet Infect Dis. 2015;15:27-35
by natalia-silvester
ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR ...
Design
Design
by test
PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV...
State of the Art Therapy for HCV
State of the Art Therapy for HCV
by liane-varnes
Last Updated: February . 21, 2014. Robert G. Gish...
HIV and HCV Update for the Pharmacist – June 2014
HIV and HCV Update for the Pharmacist – June 2014
by marina-yarberry
John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...
3 D (Paritaprevir
3 D (Paritaprevir
by myesha-ticknor
-Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in...
C-SCAPE
C-SCAPE
by pasty-toler
Design. C-SCAPE . Study. : . grazoprevir. ± . e...
SIRIUS
SIRIUS
by tawny-fly
Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1...
GZR + EBR
GZR + EBR
by celsa-spraggs
C-WORTHY Study Part C: . grazoprevir. . + . elba...
Hepatitis C Drug Pipeline
Hepatitis C Drug Pipeline
by cheryl-pisano
HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...
Dore G. J
Dore G. J
by pasty-toler
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
Randomisation
Randomisation
by pamella-moone
*. 1:1. Open-label. ≥ 18 years. HCV genotype ...
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
by tatiana-dople
dans les génotypes 1b naïfs de traitement . (1)...
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
by yoshiko-marsland
TURQUOISE-II. Phase 3. . Treatment. Naïve and ...
David Fletcher, MD
David Fletcher, MD
by tatiana-dople
Department of Medicine. University of Toronto. Co...
C-SCAPE
C-SCAPE
by tawny-fly
Design. C-SCAPE . Study. : . grazoprevir. ± . e...
C-WORTHY Study Part
C-WORTHY Study Part
by karlyn-bohler
D : . grazoprevir. . + . elbasvir. + RBV in ge...
PEG alfa-2a +
PEG alfa-2a +
by tawny-fly
RBV . versus. . PEG alfa-. 2a . versus. INF + R...
Dore G. J
Dore G. J
by myesha-ticknor
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
Ombitasvir-
Ombitasvir-
by kittie-lecroy
Paritaprevir. -. Ritonavir. . and . Dasabuvir. ...
SAPPHIRE-I
SAPPHIRE-I
by ellena-manuel
Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . ...
Elbasvir
Elbasvir
by calandra-battersby
+ . Grazoprevir. +/- Ribavirin in . Treatment-N...
SMV 12W + PEG-IFN + RBV 24-48W **
SMV 12W + PEG-IFN + RBV 24-48W **
by alexa-scheidler
SMV 24W + PEG-IFN + RBV 24-48W **. Randomisation ...
SOF/VEL + RBV
SOF/VEL + RBV
by celsa-spraggs
N = 69. >. 18 years. Failure to SOF/VEL . or ...
COSMOS
COSMOS
by sherrill-nordquist
SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 ...
Open-label
Open-label
by pamella-moone
* Liver biopsy or . Fibroscan. ≤. 12.5 . kPa....
C-WORTHY/B
C-WORTHY/B
by stefany-barnette
Randomisation*. Open-label. >. 18 years. HCV ...
Peginterferon alfa-2a +
Peginterferon alfa-2a +
by stefany-barnette
RBV . versus. Interferon alfa. -. 2a + RBV . ACT...
OBV/PTV/r DSV RBV OBV/PTV/r
OBV/PTV/r DSV RBV OBV/PTV/r
by ellena-manuel
DSV . placebo. Randomisation*. Partial blind. 1...
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...
Prevention strategies for HIV/HCV co infection
Prevention strategies for HIV/HCV co infection
by giovanna-bartolotta
Isabelle Andrieux-Meyer, MD. Médecins Sans Front...
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
by daisy
B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...
NS5A and polymerase inhibitors
NS5A and polymerase inhibitors
by LoveBug
Mark Sulkowski, MD. Professor of Medicine. Johns H...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
Sofosbuvir
Sofosbuvir
by conchita-marotz
ELECTRON (Overview): 6 parts, 22 arms. Phase . 2....
TURQUOISE-II
TURQUOISE-II
by giovanna-bartolotta
OBV/PTV/r . + . DSV . + RBV. OBV/PTV/r + . DSV . ...
The Resource Based View of the Firm (RBV)
The Resource Based View of the Firm (RBV)
by celsa-spraggs
B290. The object of strategic analysis…. Explai...